OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Dec 2020: Trial registered, NCT04676477
  2. 11 Jun 2021: Trial started, NCT04676477

The trials

NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

State
Under way
Phase
Phase 1
People
246 taking part
Started
11 Jun 2021
Primary completion
31 Jan 2025
Arms
Dose Escalation: HER3-DXd + osimertinib, Second-line Dose Expansion: HER3-DXd + osimertinib (RCD), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b)
Results
None posted
  1. 21 Dec 2020: Trial registered
  2. 11 Jun 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.